SUNWAY HEALTHCARE | Improving the lives we touch

SUNWAY HEALTHCARE HOLDINGS BERHAD
(Registration No: 202101000296 (1400594-U))

INTERIM FINANCIAL REPORT

FOR THE THIRD
QUARTER ENDED
30 SEPTEMBER 2026

No.5, Jalan Lagoon Selatan, Bandar Sunway, 47500 Selangor Darul Ehsan, Malaysia
shgir@sunwayhealthcare.com | sunwayhealthcaregroup.com

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE PERIOD ENDED 30 SEPTEMBER 2026

	NOTE	INDIVIDUAL QUARTER CURRENT YEAR QUARTER UNAUDITED 30/09/2026	INDIVIDUAL QUARTER PRECEDING YEAR CORRESPONDING QUARTER UNAUDITED 30/09/2025	INCREASE/ (DECREASE)	CUMULATIVE QUARTER CURRENT YEAR TO DATE UNAUDITED 30/09/2026	CUMULATIVE QUARTER PRECEDING YEAR CORRESPONDING PERIOD UNAUDITED 30/09/2025	INCREASE/ (DECREASE)
		RM'000	RM'000	%	RM'000	RM'000	%
REVENUE		737,441	593,126	24	1,997,385	1,585,749	26
COST OF SALES		(282,194)	(211,861)	(33)	(762,268)	(572,216)	(33)
GROSS PROFIT		455,247	381,265	19	1,235,117	1,013,533	22
OTHER INCOME		14,063	18,477	(24)	52,453	48,706	8
NET IMPAIRMENT LOSSES ON FINANCIAL ASSETS		(1,661)	(1,830)	9	(4,901)	(4,830)	(1)
ADMINISTRATIVE EXPENSES		(256,459)	(222,116)	(15)	(753,586)	(626,161)	(20)
SELLING AND MARKETING EXPENSES		(10,450)	(14,970)	30	(32,724)	(28,416)	(15)
OTHER EXPENSES		(72,970)	(71,083)	(3)	(212,830)	(197,351)	(8)
PROFIT FROM OPERATIONS		127,770	89,743	42	283,529	205,481	38
FINANCE INCOME		9,926	5,490	81	24,332	21,378	14
FINANCE COSTS		(16,444)	(16,576)	1	(49,457)	(45,083)	(10)
PROFIT BEFORE TAX	B6	121,252	78,657	54	258,404	181,776	42
TAXATION	B5	(26,081)	(18,960)	(38)	(51,752)	(41,941)	(23)
PROFIT FOR THE PERIOD		**95,171**	**59,697**	59	**206,652**	**139,835**	48
ATTRIBUTABLE TO:							
- OWNERS OF THE PARENT		95,170	59,694	59	206,657	139,830	48
- NON-CONTROLLING INTERESTS		1	3	(67)	(5)	5	>(100)
		95,171	**59,697**	59	**206,652**	**139,835**	48
EARNINGS PER SHARE ("EPS")							
- BASIC EPS (sen)	B14	0.83	0.52 [(1)]	60	1.80	1.22 [(1)]	48
- DILUTED EPS (sen)	B14	0.83	0.52 [(1)]	60	1.80	1.22 [(1)]	48

[(1)] The basic and diluted earnings per share ("EPS") for the preceding year were calculated based on the Company's enlarged share capital of 11,500,165,558 ordinary shares upon its listing.

(The Unaudited Condensed Consolidated Income Statements should be read in conjunction with the Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 SEPTEMBER 2026

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	CURRENT YEAR QUARTER UNAUDITED 30/09/2026	PRECEDING YEAR CORRESPONDING QUARTER UNAUDITED 30/09/2025	CURRENT YEAR TO DATE UNAUDITED 30/09/2026	PRECEDING YEAR CORRESPONDING PERIOD UNAUDITED 30/09/2025
	RM'000	RM'000	RM'000	RM'000
PROFIT FOR THE PERIOD	95,171	59,697	206,652	139,835
OTHER COMPREHENSIVE LOSS TO BE RECLASSIFIED TO PROFIT OR LOSS IN SUBSEQUENT PERIODS				
FOREIGN CURRENCY TRANSLATION DIFFERENCES FOR FOREIGN OPERATIONS	(26)	(131)	(45)	(152)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD	(26)	(131)	(45)	(152)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**95,145**	**59,566**	**206,607**	**139,683**
ATTRIBUTABLE TO:				
- OWNERS OF THE PARENT	95,144	59,563	206,612	139,678
- NON-CONTROLLING INTERESTS	1	3	(5)	5
	95,145	**59,566**	**206,607**	**139,683**

(The Unaudited Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2026

	NOTE	AS AT END OF CURRENT PERIOD UNAUDITED 30/09/2026	AS AT PRECEDING FINANCIAL PERIOD END AUDITED 31/12/2025	
		RM'000	RM'000	
ASSETS				
Non-current assets				
Property, plant and equipment		3,756,473	3,676,463	
Intangible assets		32,363	33,729	
Lease receivables		12,313	13,251	
Goodwill		2,349	2,349	
Deferred tax assets		48,834	57,247	
Other investments		22	22	
		3,852,354	**3,783,061**	
Current assets				
Inventories		121,808	96,107	
Trade receivables	B11	412,260	305,184	
Other receivables		163,695	103,612	
Lease receivables		1,258	1,209	
Amounts due from related parties		1,520	3,836	
Tax recoverable		5,415	5,213	
Cash and bank balances		1,151,676	543,282	
		1,857,632	**1,058,443**	
TOTAL ASSETS		**5,709,986**	**4,841,504**	
EQUITY AND LIABILITIES				
Current liabilities				
Borrowings	B8	548,500	303,304	
Trade payables		299,959	285,580	
Other payables		340,163	270,690	
Amounts due to related parties		36,062	54,218	
Derivative financial instruments	B9	1,469	3,653	
Lease liabilities		17,843	7,890	
Tax payable		24,263	11,136	
		1,268,259	**936,471**	
Non-current liabilities				
Borrowings	B8	893,500	1,287,000	
Deferred tax liabilities		76,586	78,439	
Lease liabilities		20,006	18,883	
		990,092	**1,384,322**	
Total liabilities		**2,258,351**	**2,320,793**	
Equity attributable to Owners of the Parent				
Share capital		2,998,910	2,174,189	
Reserves		452,657	346,512	
		3,451,567	2,520,701	
Non-controlling interests		68	10	
Total equity		**3,451,635**	**2,520,711**	
TOTAL EQUITY AND LIABILITIES		**5,709,986**	**4,841,504**	
Number of ordinary shares ('000)		11,504,773	11,500,166	
Net assets per share attributable to Owners of the Parent (RM)		0.30	0.22	*

*Net assets per ordinary share as at 31 December 2025 was calculated based on the Company's enlarged share capital of 11,500,165,558 ordinary shares upon its Listing.

(The Unaudited Condensed Consolidated Statements of Financial Position should be read in conjunction with the Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 SEPTEMBER 2026

	I----------ATTRIBUTABLE TO OWNERS OF THE PARENT ----------I							
	I---------- NON-DISTRIBUTABLE ----------I			DISTRIBUTABLE				
	SHARE CAPITAL RM'000	EXCHANGE TRANSLATION RESERVE RM'000	SHARE OPTION RESERVE RM'000	RETAINED EARNINGS RM'000	TOTAL RESERVES RM'000	TOTAL ATTRIBUTABLE TO OWNERS OF THE PARENT RM'000	NON-CONTROLLING INTERESTS RM'000	TOTAL EQUITY RM'000
PERIOD ENDED 30 SEPTEMBER 2026								
At 1 January 2026	**2,174,189**	**(763)**	**-**	**347,275**	**346,512**	**2,520,701**	**10**	**2,520,711**
Profit for the financial period	-	-	-	206,657	206,657	**206,657**	(5)	**206,652**
Other comprehensive loss, net of tax	-	(45)	-	-	(45)	**(45)**	-	**(45)**
Total comprehensive (loss)/income	**-**	**(45)**	**-**	**206,657**	**206,612**	**206,612**	**(5)**	**206,607**
Transaction with owners								
Issuance of ordinary shares pursuant to Initial Public Offering ("IPO")	833,762	-	-	-	-	**833,762**	-	**833,762**
Share issuance costs	(16,598)	-	-	-	-	**(16,598)**	-	**(16,598)**
Issuance of ordinary shares pursuant to Employee Share Options Scheme ("ESOS")	7,557	-	(875)	-	(875)	**6,682**	-	**6,682**
Share option granted under ESOS	-	-	5,647	-	5,647	**5,647**	-	**5,647**
Issuance of ordinary shares by subsidiary to non-controlling interests	-	-	-	-	-	**-**	65	**65**
Dividends paid	-	-	-	(105,239)	(105,239)	**(105,239)**	-	**(105,239)**
Dividends paid to non-controlling interests	-	-	-	-	-	**-**	(2)	**(2)**
Total transactions with owners	824,721	-	4,772	(105,239)	(100,467)	**724,254**	63	**724,317**
At 30 September 2026	**2,998,910**	**(808)**	**4,772**	**448,693**	**452,657**	**3,451,567**	**68**	**3,451,635**
PERIOD ENDED 30 SEPTEMBER 2025								
At 1 January 2025	**2,174,189**	**(485)**	**-**	**717,563**	**717,078**	**2,891,267**	**9**	**2,891,276**
Profit for the financial period	-	-	-	139,830	139,830	**139,830**	5	**139,835**
Other comprehensive loss, net of tax	-	(152)	-	-	(152)	**(152)**	-	**(152)**
Total comprehensive (loss)/income	**-**	**(152)**	**-**	**139,830**	**139,678**	**139,678**	**5**	**139,683**
Transaction with owners								
Dividends paid	-	-	-	(611,250)	(611,250)	**(611,250)**	-	**(611,250)**
Dividends paid to non-controlling interests	-	-	-	-	-	-	(5)	**(5)**
Total transaction with owners	-	-	-	(611,250)	(611,250)	**(611,250)**	(5)	**(611,255)**
At 30 September 2025	**2,174,189**	**(637)**	**-**	**246,143**	**245,506**	**2,419,695**	**9**	**2,419,704**

(The Unaudited Condensed Consolidated Statements of Changes in Equity should be read in conjunction with Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

SUNWAY HEALTHCARE HOLDINGS BERHAD (Registration No: 202101000296 (1400594-U))
QUARTERLY REPORT ON THE CONSOLIDATED RESULTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2026
THE FIGURES HAVE NOT BEEN AUDITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED 30 SEPTEMBER 2026

	FOR THE 9 MONTHS PERIOD ENDED UNAUDITED 30/09/2026	FOR THE 9 MONTHS PERIOD ENDED UNAUDITED 30/09/2025
	RM'000	RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	258,404	181,776
Adjustments for:		
Depreciation and amortisation:		
- property, plant and equipment	151,207	127,179
- intangible assets	9,234	8,545
- right-of-use assets	12,029	4,488
Finance income	(24,332)	(21,378)
Interest expenses	49,457	44,048
Net unrealised loss on foreign exchange	3,379	(2,303)
Loss/(Gain) on lease reassessment	4,012	(5,032)
(Gain)/ Loss on disposal of property, plant and equipment	(76)	225
Share options expenses	5,647	-
Fair value (gain)/loss on derivative financial instruments	(2,650)	297
Net impairment losses/(reversal of impairment losses) on:		
- trade receivables	4,674	4,861
- other receivables	2	(15)
- amounts due from related parties	-	(16)
Write down/(write back) of inventories	284	(36)
Write off:		
- trade receivables	1,035	-
- inventories	342	103
- property, plant and equipment	271	196
Operating profit before working capital changes	472,919	342,938
Changes in working capital		
Inventories	(26,326)	(7,996)
Trade receivables	(115,698)	(42,941)
Other receivables	(58,955)	(23,881)
Amounts due from related parties	2,317	5,997
Trade payables	14,379	58,694
Other payables	42,766	(32,826)
Amounts due to related parties	(18,516)	(7,041)
Cash generated from operations	312,886	292,944
Tax paid	(39,374)	(28,970)
Tax refunded	7,058	9
Net cash from operating activities	**280,570**	**263,983**

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED 30 SEPTEMBER 2026 (CONT'D)

	NOTE	FOR THE 9 MONTHS PERIOD ENDED UNAUDITED 30/09/2026	FOR THE 9 MONTHS PERIOD ENDED UNAUDITED 30/09/2025
		RM'000	RM'000
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from disposal of property, plant & equipment		139	1,713
Acquisition of property, plant and equipment		(201,448)	(389,259)
Acquisition of intangible assets		(4,492)	(2,243)
Interest received		24,332	21,378
Net cash used in investing activities		**(181,469)**	**(368,411)**
CASH FLOWS FROM FINANCING ACTIVITIES			
Drawdowns of borrowings		788,396	872,348
Repayments of borrowings		(936,700)	(380,071)
Proceeds from settlement of previously unpaid ordinary shares		-	28,500
Net proceeds from the issuance of ordinary shares pursuant to the IPO	B15	817,164	-
Proceeds from the issuance of ordinary shares pursuant to the ESOS		6,682	-
Proceeds from issuance of shares by subsidiary to non-controlling interests		65	-
Payments of lease liabilities		(13,436)	(4,225)
Interest paid		(47,668)	(44,048)
Dividends paid		(105,239)	(611,250)
Dividends paid to non-controlling interests of subsidiaries		(2)	(5)
Net cash from/(used in) financing activities		**509,262**	**(138,751)**
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS		608,363	(243,179)
EFFECTS OF EXCHANGE RATE CHANGES		31	(337)
CASH AND CASH EQUIVALENTS AT BEGINNING OF FINANCIAL YEAR		543,282	767,959
CASH AND CASH EQUIVALENTS AT END OF FINANCIAL PERIOD		**1,151,676**	**524,443**
Cash at banks and on hand		122,890	217,337
Short term funds			
- Money market funds		1,028,786	307,106
CASH AND CASH EQUIVALENTS		**1,151,676**	**524,443**

(The Unaudited Condensed Consolidated Statements of Cash Flows should be read in conjunction with Annual Statutory Financial Statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.)

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

A1. Accounting Policies and Basis of Preparation

The interim financial report is unaudited and has been prepared in accordance with MFRS 134 *Interim Financial Reporting* issued by the Malaysian Accounting Standards Board ("MASB") and Paragraph 9.22 and Appendix 9B of Bursa Malaysia Securities Berhad ("Bursa Securities") Listing Requirements.

The interim financial report should be read in conjunction with the audited financial statements for the year ended 31 December 2025 and the accompanying explanatory notes attached to this interim financial report.

The accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the annual financial statements for the financial year ended 31 December 2025, except for the adoption of the following Amendments to MFRS and Annual Improvements that became effective on 1 January 2026, as disclosed below:

Title	Effective Date
Amendments to the Classification and Measurement of Financial Instruments (Amendments to MFRS 9 and MFRS 7)	1 January 2026
Annual Improvements to MFRS Accounting Standards - Volume 11	1 January 2026
Contracts Referencing Nature-dependent Electricity (Amendments to MFRS 9 and MFRS 7)	1 January 2026

The adoption of these pronouncements did not have a material impact on the Group's interim financial report for the financial period ended 30 September 2026.

A2. Report of the Auditors

The report of the auditors of preceding annual financial statements was not subject to any qualification.

A3. Seasonal or Cyclical Factors of Operations

The results for the current quarter under review were not materially affected by seasonal or cyclical factors of operations.

A4. Material Unusual Items

There were no material unusual items affecting the amounts reported for the current quarter under review.

A5. Material Changes in Estimates

There were no material changes in estimates of amounts reported in prior financial year that have a material effect on the results for the current financial period under review.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A6. Issuances, Cancellations, Repurchases, Resales and Repayments of Equity Securities

(a) Pursuant to the Company's listing on the Main Market of Bursa Securities ("Listing"), an IPO comprising up to 1,968,996,020 ordinary shares was undertaken and structured as follows:

(i) Public Issue of 575,008,300 new ordinary shares in the Company ("Issue Shares"), involving:
- 230,003,400 Issue Shares made available for application by the Malaysian public, of which 115,001,700 Issue Shares were set aside for application by Bumiputera citizens, companies, cooperatives, societies and institutions;
- 115,001,700 Issue Shares made available to the Directors and eligible employees of the Group, persons who have contributed to the success of the Group, Directors of Sunway Berhad ("Sunway") and eligible employees of Sunway Group;
- 230,003,200 Issue Shares made available for application by institutional and selected investors; and

(ii) Offer for sale of 1,393,987,720 existing shares ("Offer Shares") made available by way of private placement to Bumiputera investors approved by the Ministry of Investment, Trade and Industry of Malaysia ("MITI"), as well as institutional and selected investors.

The IPO was completed and the Company was listed on the Main Market of Bursa Malaysia Securities Berhad on 18 March 2026 with an enlarged issued share capital of 11,500,165,558 ordinary shares.

(b) During the current financial period, 4,607,500 ordinary shares were issued pursuant to the exercise of employees' share options granted under the Employees Share Option Scheme.

Save as disclosed, there were no other issuances, cancellations, repurchases, resales and repayments of equity securities for the current financial period under review.

A7. Dividends Paid

During the current financial period ended 30 September 2026, the dividends declared and paid by the Company were as follows:

(a) The Company has on 4 February 2026 declared and paid a single-tier interim dividend of 8.24 sen per ordinary share amounting to RM100,000,000 to all members who are registered in the Register of Members as at 3 February 2026 in respect of the financial year ending 31 December 2026.

(b) The Company has on 19 March 2026 declared and paid a single-tier dividend of 0.3 sen per ordinary share amounting to RM5,239,726.03 to Greenwood Capital Pte Ltd in respect of the financial year ending 31 December 2026, pursuant to Clause 10.6 of the Shareholders' Agreement ("SA") and Clause 4(f) of the 3rd supplemental agreement ("3rd Supplemental SSA"). Sunway City Sdn. Bhd. had waived its entitlement to the distribution of this dividend.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A8. Segmental Reporting

For management purposes, the Group is organised into two (2) reportable segments based on their product and services. The reportable segments are summarised as follows:

(i) Hospital operations - operation of medical centres and provision of medical consultation services.

(ii) Others - investment holding activities, provision of financial services, senior living care and assistance, operation of traditional and complementary medicine centre, provision of nursing care services, provision of ambulatory care services, provision of training services, leasing of properties and other related activities.

Management monitors the operating results of its business units separately for the purposes of resource allocation and performance evaluation. Segment results, assets and liabilities include items that are directly attributable to a segment as well as those that can be allocated on a reasonable and consistent basis. Unallocated items comprise corporate assets, liabilities and expenses.

Segmental results for the financial period ended 30 September 2026 are as follows:

	Hospital operations RM'000	Others RM'000	Eliminations RM'000	Total RM'000
Revenue				
Sales to external customers	1,959,138	38,247	-	1,997,385
Inter-segment revenue	7,024	838	(7,862)	-
Total revenue	**1,966,162**	**39,085**	**(7,862)**	**1,997,385**
Results				
Earnings Before Interest, Taxation, Depreciation and Amortisation ("EBITDA") *	**488,111**	**(32,112)**	**-**	**455,999**
Profit/(loss) from operations	323,528	(39,999)	-	283,529
Finance income	4,333	123,416	(103,417)	24,332
Finance costs	(91,895)	(60,979)	103,417	(49,457)
Profit before tax	235,966	22,438	-	258,404
Taxation	(38,493)	(13,259)	-	(51,752)
Profit for the period	197,473	9,179	-	206,652
Non-controlling interests	-	-	5	5
Attributable to owners of the parent	**197,473**	**9,179**	**5**	**206,657**

	Hospital operations RM'000	Others RM'000	Eliminations RM'000	Total RM'000
OTHER SEGMENT INFORMATION				
Depreciation and amortisation	164,584	7,886	-	172,470
Capital expenditure	225,888	7,068	-	232,956

Segmental assets and liabilities as at 30 September 2026 are as follows:

	Hospital operations RM'000	Others RM'000	Eliminations RM'000	Total RM'000
Assets				
Segment assets	4,431,752	6,397,034	(5,173,049)	5,655,737
Unallocated assets				54,249
Total assets				**5,709,986**
Liabilities				
Segment liabilities	3,166,766	2,329,981	(3,339,245)	2,157,502
Unallocated liabilities				100,849
Total liabilities				**2,258,351**

* EBITDA is calculated as profit/(loss) for the period, plus taxation, finance costs and depreciation and amortisation, less finance income.

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A9. Valuation of Property, Plant and Equipment

All items of property, plant and equipment (excluding right-of-use assets) are initially recorded at cost. Subsequent to initial recognition, such assets are carried at cost less any accumulated depreciation and any accumulated impairment losses. There was no revaluation of freehold land and buildings for the current financial period.

A10. Material Events Subsequent to the end of the Reporting Period

(a) On 21 October 2026, Sunway Medical Centre Penang Sdn Bhd ("SMCP"), a wholly-owned subsidiary of the Company, entered into a first supplemental agreement ("First Supplemental Agreement") with RHB Trustees Berhad (trustee of Sunway Real Estate Investment Trust) ("Vendor"), to supplement, amend or vary the conditional sale and purchase agreement dated 28 October 2025, as disclosed in the Prospectus, for the acquisition by SMCP of the Sunway Hotel Seberang Jaya Property (comprising the leasehold land of approximately 4,294 square metres, the hotel building erected thereon and the related fixtures, fittings, equipment and tangible property) for a total cash consideration of RM60.0 million. The First Supplemental Agreement:

(i) amends the Cut-Off Date to 28 July 2027 (or such other date as the parties may mutually agree in writing), to provide the Vendor with additional time to fulfil the conditions precedent;

(ii) amends the payment terms such that the balance purchase price shall be paid within three (3) months from the date the last of the conditions precedent is fulfilled or waived (or such extended period as mutually agreed in writing);

(iii) updates the land particulars following the lease extension; and

(iv) makes consequential amendments to the notice provisions.

(b) On 21 October 2026, Sunway Healthcare Ventures Sdn Bhd, a wholly-owned subsidiary of the Company, entered into a Joint Venture and Shareholders Agreement with Tapak Senja Sdn Bhd, a wholly-owned subsidiary of Putrajaya Holdings Sdn Bhd, following the Heads of Agreement signed on 23 April 2025. The agreement establishes a strategic 60:40 joint venture to develop Sunway Medical Centre Putrajaya, a planned 325-bed multi-specialty tertiary private hospital on approximately 2.5 acres of freehold land held under Geran 9849, Lot 10007, Precinct 7, Putrajaya, adjacent to Putrajaya Sentral, together with the execution of Parent Company Guarantees.

(c) On 29 October 2026, the conditions precedent under the sale and purchase agreement dated 24 December 2025 ("Tower A SPA") entered into between Sunway Medical 3C4 Sdn Bhd (formerly known as Sunway Iskandar Medical Centre Sdn Bhd) ("SM3C4"), a subsidiary of the Company, and Sunway Integrated Properties Sdn Bhd ("SIP") in relation to the proposed acquisition of the lower 12 of the 22 floors of Tower A of Sunway Medical Centre Velocity for a total purchase consideration of RM228.5 million ("Proposed Acquisition") were fulfilled. Accordingly, the Tower A SPA became unconditional on 29 October 2026. The balance purchase consideration of RM205.65 million is payable by SM3C4 to SIP within the three (3)-month completion period ending on 29 January 2027.

Save as disclosed, there were no other material events subsequent to the end of the reporting period under review that have not been reflected in this interim financial report.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A11. Changes in the Composition of the Group

(a) On 5 June 2026, Sunway Medical 3C4 Sdn. Bhd. ("SM3C4") (formerly known as Sunway Iskandar Medical Centre Sdn Bhd), an indirect subsidiary of Sunway Healthcare Holdings Berhad ("SHH" or the "Company"), completed an allotment of 249,998 new ordinary shares at an issue price of RM1.00 per share for a total cash consideration of RM249,998. Following the allotment, the issued share capital of SM3C4 increased from 2 ordinary shares to 250,000 ordinary shares. Of the 249,998 new ordinary shares issued, 184,998 shares were allotted to SHH and 65,000 shares were allotted to RKRH Sdn. Bhd. As a result, SHH's equity interest in SM3C4 decreased from 100% to 74%. The allotment is not expected to have any material effect on the earnings per share, net assets per share, gearing, issued share capital, or substantial shareholders' shareholdings of SHH for the current financial year.

(b) On 18 June 2026, Sunway Healthcare Ventures Sdn. Bhd. ("SHV"), a wholly-owned subsidiary of the Company, was incorporated in Malaysia with an issued share capital of RM2 comprising 2 ordinary shares. SHV was incorporated to undertake investment holding and such other activities as may be determined by the Company from time to time.

Save as disclosed, there were no other significant changes in the composition of the Group for the current financial period ended 30 September 2026.

A12. Contingent Liabilities and Assets

There were no material changes in contingent liabilities or contingent assets of the Group as at the date of this report.

A13. Commitments

Capital commitments not provided for in the financial period ended 30 September 2026 are as follows:

	30/09/2026 RM'000	31/12/2025 RM'000
Approved and contracted for property, plant and equipment and intangible assets	332,725	309,854
Approved but not contracted for property, plant and equipment and intangible assets	2,008,821	1,979,363
	2,341,546	**2,289,217**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

A14. Significant Related Party Transactions

The significant related party transactions set out below were carried out in the normal course of business and on terms and conditions not materially different from those obtainable in transactions with unrelated parties.

	Current Quarter Ended		Cumulative Year To Date	
	30/09/2026	30/09/2025	30/09/2026	30/09/2025
	RM'000	RM'000	RM'000	RM'000
Transactions with Sunway Construction Group Berhad Group				
Provision of construction, building works and services	(20,503)	(29,345)	(87,239)	(86,749)
Sales and provision of medical services	47	27	264	1,240
Transactions with Sunway Berhad Group				
Sales and provision of medical services	1,756	772	3,568	2,445
Provision of information technology, computer products software support, maintenance and consultancy services	(2,556)	(1,252)	(5,641)	(5,694)
Leasing and rental of premises/ properties	(3,375)	(694)	(10,022)	(1,155)
Provision of car park management, carpark rental and related services	(418)	(336)	(1,966)	(1,168)
Provision of hotel accommodation, food & beverage and related services	(1,268)	(1,569)	(3,993)	(2,704)
Provision of Human Resources administrative services	(574)	(397)	(2,115)	(1,599)
Provision of interior decorations and related services, and renovation works	(1,284)	(4,731)	(4,011)	(14,405)
Provision of management services, trademark license fee and other related services	(1,605)	(228)	(5,110)	(2,227)
Provision of project management services	(410)	(1,896)	(2,490)	(4,691)
Deposits paid on land acquisition	(26,258)	-	(28,324)	-

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of Financial Performance

Analysis of performance of the respective operating segments are as follows:

	Individual Quarter ended			Cumulative Quarter ended		
	30/09/2026	30/09/2025	Increase/ (Decrease)	30/09/2026	30/09/2025	Increase/ (Decrease)
	RM'000	RM'000	%	RM'000	RM'000	%
Revenue						
Hospital operations	723,072	577,903	25	1,959,138	1,554,618	26
Others	14,369	15,223	(6)	38,247	31,131	23
	737,441	**593,126**	24	**1,997,385**	**1,585,749**	26
EBITDA						
Hospital operations	198,587	144,829	37	488,111	352,525	38
Others	(13,386)	(4,490)	>(100)	(32,112)	(6,832)	>(100)
	185,201	**140,339**	32	**455,999**	**345,693**	32
Profit Before Tax						
Hospital operations	114,248	72,099	58	235,966	150,962	56
Others	7,004	6,558	7	22,438	30,814	(27)
	121,252	**78,657**	54	**258,404**	**181,776**	42

Quarter ended 30 September 2026 compared with quarter ended 30 September 2025 (“year-on-year" or “y-o-y")

The Group recorded revenue of RM737.4 million and EBITDA of RM185.2 million for the current quarter ended 30 September 2026, compared with revenue of RM593.1 million and EBITDA of RM140.3 million in the corresponding quarter of the previous financial period. Revenue increased by 24% y-o-y, mainly driven by higher contributions from the hospital operations segment. EBITDA increased by 32%, supported by stronger operating performance in the hospital operations segment. Profit before tax rose 54% y-o-y, driven by the higher EBITDA achieved during the quarter, partially offset by increased depreciation expenses arising from the Group's ongoing capacity expansion initiatives.

The hospital operations segment recorded revenue of RM723.1 million in the current quarter, compared with RM577.9 million in the corresponding quarter of the previous financial period, representing an increase of 25%. The growth was mainly attributable to higher patient volumes across the Group's hospitals, as well as increased revenue contributions from Sunway Medical Centre ("SMC") Ipoh, Damansara, Velocity and Penang. Foreign patient revenue increased by 2% to RM91.2 million, from RM89.4 million in the corresponding quarter of the previous financial year. The growth was primarily driven by higher patient inflows from Indonesia, China and Cambodia.

The Group’s overall bed occupancy rate for the current quarter was 77% compared with 71% in the corresponding quarter of the previous financial period. In Q3 2026, inpatient admissions in the hospital operations segment increased by 21% to 36,541, while average revenue per inpatient admission grew by 5% to RM12,339. EBITDA growth was supported by stronger operational performance across the hospital operations segment, underpinned by higher patient activity and revenue growth, partially offset by higher operating expenses including staff costs and other non-recurring costs.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B1. Review of Financial Performance (Cont'd)

Year-to-date ended 30 September 2026 compared with year-to-date ended 30 September 2025

For the nine-month period ended 30 September 2026, the Group recorded revenue of RM1,997.4 million and EBITDA of RM456.0 million, compared with revenue of RM1,585.7 million and EBITDA of RM345.7 million in the corresponding period of the previous year. This represents a 26% y-o-y increase in revenue and a 32% increase in EBITDA. The higher revenue was driven by stronger contributions across all business segments, while the improvement in EBITDA was primarily attributable to stronger operating performance from the hospital operations segment. Profit before tax increased by 42% to RM258.4 million, from RM181.8 million in the corresponding period of the previous year, broadly in line with the increase in EBITDA, partially offset by higher depreciation expenses associated with the Group's capacity expansion.

The hospital operations segment recorded revenue of RM1,959.1 million for the current nine-month period ended 30 September 2026, compared with RM1,554.6 million in the corresponding period of the previous year, representing a 26% increase. The growth was primarily driven by stronger contributions across all hospitals within the Group. Foreign patient revenue increased significantly by 23% to RM262.8 million, compared with RM213.2 million in the corresponding period of the previous year, mainly attributable to higher patient arrivals from Indonesia, China and Cambodia.

The Group's overall bed occupancy rate improved to 72%, compared with 69% in the corresponding period of the previous year. In support of growing patient demand, the Group expanded its total licensed bed capacity from 1,662 beds to 1,994 beds as at 30 September 2026, representing an addition of 332 beds or a 20% y-o-y increase. Inpatient admissions increased by 18% y-o-y to 97,965, while average revenue per inpatient admission rose by 8% to RM12,456, reflecting higher inpatient volumes and improved case mix. Accordingly, EBITDA growth was supported by stronger operational performance across the hospital operations segment, partially offset by higher operating expenses, including staff costs and other non-recurring expenses.

B2. Material Changes in the Quarterly Results

Analysis of performance of the respective operating segments are as follows:

	Quarter ended		
	30/09/2026 RM'000	30/06/2026 RM'000	Increase/ (Decrease) %
Revenue			
Hospital operations	723,072	659,247	10
Others	14,369	13,652	5
	737,441	**672,899**	10
EBITDA			
Hospital operations	198,587	163,674	21
Others	(13,386)	(4,904)	>(100)
	185,201	**158,770**	17
Profit Before Tax			
Hospital operations	114,248	77,709	47
Others	7,004	15,534	(55)
	121,252	**93,243**	30

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B2. Material Changes in the Quarterly Results (Cont'd)

Quarter ended 30 September 2026 compared with preceding quarter ended 30 June 2026 (“quarter-on-quarter" or “q-o-q")

For the current quarter, the Group recorded revenue of RM737.4 million and EBITDA of RM185.2 million, compared with revenue of RM672.9 million and EBITDA of RM158.8 million in the preceding quarter. This represents a 10% q-o-q increase in revenue and a 17% q-o-q increase in EBITDA. The stronger performance was primarily driven by broad-based growth across the hospital operations. Profit before tax increased by 30% to RM121.3 million in the current quarter from RM93.2 million in the preceding quarter, supported by the stronger operational performance.

The hospital operations segment recorded revenue of RM723.1 million during the current quarter, compared with RM659.2 million in the preceding quarter, representing a 10% q-o-q increase. The growth was driven by improved operational performance and patient activity levels. Foreign patient revenue increased by 7% to RM91.2 million, compared with RM84.9 million in the preceding quarter. The Group's overall bed occupancy rate improved to 77% in the current quarter from 73% in the preceding quarter. During the quarter, the Group's total licensed bed capacity increased from 1,855 beds as at 30 June 2026 to 1,994 beds as at 30 September 2026, representing an addition of 139 beds or a 7% q-o-q increase. Inpatient admissions increased by 12% to 36,541, while revenue per inpatient admission slightly declined by 1% to RM12,339. Consequently, EBITDA for the hospital operations segment increased q-o-q, supported by higher revenue and increased patient volumes, partially offset by higher operating expenses, including staff costs and other non-recurring expenses.

B3. Prospects

The third quarter of 2026 ("Q3FY2026") sustained the Group's growth momentum, supported by broad-based increases in patient volumes, higher bed utilisation and resilient revenue intensity across its hospital network. Patient demand continued to absorb the Group's expanded capacity, with occupancy improving notwithstanding the significant increase in licensed beds. The continued ramp-up of the newer hospitals, particularly SMC Damansara and SMC Ipoh, contributed to stronger profitability and operating leverage, reinforcing the Group's earnings performance for the nine months ended 30 September 2026. With patient activity continuing to strengthen and additional capacity being progressively absorbed, the Group is well-positioned to sustain its operating momentum into the final quarter of 2026 and beyond.

As at 30 September 2026, the Group had 1,994 licensed beds and a further 277 completed beds available for licensing, bringing total capacity to 2,271 beds. Following the opening of SMC Sunway City's Tower F in August 2026, 108 of its 216 beds were licensed during the quarter, strengthening the flagship hospital's capacity and specialised paediatric offerings. Meanwhile, expansion works for Phase 3 of SMC Penang commenced during the quarter, with the development expected to add 105 beds by the second half of 2028. Together, these initiatives are expected to increase total bed capacity to approximately 2,400 beds by 2028, supported by specialist recruitment, service expansion and continued improvements in hospital utilisation. The Group will continue to progressively license and operationalise its remaining completed capacity, alongside ongoing brownfield expansion initiatives at SMC Damansara and SMC Penang. In senior living, renovation works for an additional 256 rooms at Sunway Sanctuary commenced during Q3FY2026, with completion targeted for the fourth quarter of 2027 to accommodate further growth.

In parallel, the Group achieved several key milestones in its greenfield expansion programme, including the groundbreaking of SMC Iskandar Puteri in September 2026, the execution of the land acquisition agreement for SMC Seremban Sentral in September 2026, and the formalisation of its joint venture with Putrajaya Holdings Sdn Bhd in October 2026. Alongside the continued development of its ambulatory care centre network, these initiatives form part of the Group's strategy to expand its geographical presence and increase its hospital network capacity to more than 3,400 beds by 2032, subject to the relevant approvals and prevailing project timelines.

The healthcare financing landscape continues to evolve, with the MediAsas initiative progressing towards its scheduled nationwide rollout by end-January 2027, supported by the establishment of an independent governance board and measures under Budget 2027 to encourage broader medical insurance participation. The Group has also observed signs of stabilisation in insurer discount pressures compared with prior years. As the Diagnosis-Related Group ("DRG") payment framework and related healthcare reforms continue to develop, greater emphasis is expected on affordability, transparency and sustainable healthcare costs. The Group will continue to engage constructively with insurers, takaful operators and relevant stakeholders towards sustainable reimbursement arrangements that balance affordability, accessibility and quality of care.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B3. Prospects (Cont'd)

Medical tourism remains an important strategic growth driver for the Group, with foreign patient revenue recording sequential improvement in Q3FY2026 despite ongoing geopolitical uncertainties, elevated airfares and evolving regional travel patterns. The Group will continue to diversify its international patient source markets, strengthen referral and payor partnerships, and expand higher-value specialist services to support revenue intensity and profitability. At the same time, the Group remains attentive to evolving operating cost pressures, with continued emphasis on disciplined pricing and discount governance, procurement efficiencies, clinical cost management and improvements in operating productivity to support margin resilience.

Supported by favourable long-term healthcare demographics, Malaysia's established position as a regional medical tourism destination, and the Group's expanding capacity and clinical capabilities, the Group remains positive about its prospects for FY2026 and beyond. The Group will continue to focus on translating patient-volume growth, capacity activation and the progressive maturation of its hospitals into sustainable earnings, while strengthening specialist capabilities and maintaining clinical excellence, operational resilience and disciplined capital deployment.

B4. Variance of Actual Profit from Profit Forecast

The Company did not issue any profit forecast or profit guarantee during the current year under review.

B5. Taxation

	Individual Quarter		Cumulative Quarter	
	Current Quarter 30/09/2026 RM'000	Preceding Year Corresponding Quarter 30/09/2025 RM'000	Current Year To Date 30/09/2026 RM'000	Preceding Year Corresponding Period 30/09/2025 RM'000
Current taxation	(25,317)	(4,012)	(47,184)	(27,880)
Over provision of tax in prior years	1,941	1,514	1,941	1,514
Deferred taxation	(2,705)	(16,462)	(6,509)	(15,575)
	(26,081)	**(18,960)**	**(51,752)**	**(41,941)**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B6. Profit before Tax

The following amounts have been included in arriving at profit before tax:

	Current Quarter 30/09/2026 RM'000	Cumulative Year To Date 30/09/2026 RM'000
Interest income	9,926	24,332
Interest expenses	(16,444)	(49,457)
Net (impairment losses)/reversal of impairment on:		
- Trade receivables	(1,434)	(4,674)
- Other receivables	(2)	(2)
Share options expenses	(2,460)	(5,647)
Depreciation and amortisation	(57,431)	(172,470)
Net gain on disposal of property, plant and equipment	14	76
Loss on lease reassessment	(4,012)	(4,012)
Fair value (loss)/gain on derivative financial instruments	(665)	2,650
Net unrealised foreign exchange gains/(losses)	(1,064)	(3,379)
Write down of inventories	(64)	(284)
Written off:-		
- Property, plant and equipment	(121)	(271)
- Inventories	(163)	(342)
- Trade Receivables	(227)	(1,035)

B7. Status of Corporate Proposal Announced

(a) On 18 November 2024, Sunway Medical Centre Sdn Bhd (“SMC”) entered into a sale and purchase agreement with Sunway Marketplace Sdn Bhd for the acquisition of a registered lease over a parcel of land measuring approximately 5.45 acres in Sunway City Iskandar Puteri for the development of Sunway Medical Centre Iskandar Puteri (“Existing SPA”). Subsequently, on 29 July 2026, SMC entered into a sale and purchase agreement with Sunway Marketplace Sdn Bhd, Sunway Parkview Sdn Bhd and Sunway Iskandar Sdn Bhd to acquire four parcels of freehold land measuring approximately 9.918 acres for a total cash consideration of RM45.37 million (“SPA”). The Existing SPA has been terminated on 29 July 2026 following the execution of the SPA. The acquisition replaces the earlier proposed lease acquisition and secures a larger land area within Sunway City Iskandar Puteri, providing greater flexibility for the development and future expansion of Sunway Medical Centre Iskandar Puteri, a proposed 410-bed tertiary hospital.

(b) On 21 October 2026, Sunway Medical Centre Penang Sdn. Bhd. ("SMCP") (as purchaser) entered into a first supplemental agreement (“First Supplemental Agreement”) with RHB Trustees Berhad (as trustee of Sunway REIT) (as vendor) to supplement, amend or vary the conditional sale and purchase agreement dated 28 October 2025, as disclosed in the Prospectus, for the acquisition by SMCP of the Sunway Hotel Seberang Jaya Property (comprising the leasehold land of approximately 4,294 square metres, the hotel building erected thereon and the related fixtures, fittings, equipment and tangible property) for a total cash consideration of RM60.0 million. The First Supplemental Agreement extends the Cut-Off Date to 28 July 2027 (or such other date as the parties may mutually agree in writing), to provide the Vendor with additional time to fulfil the conditions precedent. Please refer to Note A10 for further details.

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B7. Status of Corporate Proposal Announced (Cont'd)

(c) On 29 October 2026, the conditions precedent under the sale and purchase agreement dated 24 December 2025 (“Tower A SPA”) entered into between Sunway Medical 3C4 Sdn Bhd (formerly known as Sunway Iskandar Medical Centre Sdn Bhd) (“SM3C4”), a subsidiary of the Company, and Sunway Integrated Properties Sdn Bhd (“SIP”), in relation to the proposed acquisition of the lower 12 of the 22 floors of Tower A of Sunway Medical Centre Velocity (approximately 24,858 square metres) for a total purchase consideration of RM228.5 million (“Proposed Acquisition”), as disclosed in the Prospectus, were fulfilled. Accordingly, the Tower A SPA became unconditional on 29 October 2026. The three (3)-month completion period commenced on 29 October 2026 and will end on 29 January 2027, within which the balance purchase consideration of RM205.65 million is payable by SM3C4 to SIP. The Proposed Acquisition has not been completed as at the date of this report.

(d) On 21 October 2026, Sunway Healthcare Ventures Sdn Bhd, a wholly-owned subsidiary of Sunway Healthcare Holdings Berhad (“SHH”), entered into a Joint Venture and Shareholders Agreement with Tapak Senja Sdn Bhd, a wholly-owned subsidiary of Putrajaya Holdings Sdn Bhd (“PjH”), following the Heads of Agreement entered into between SHH and PjH on 23 April 2025. The agreement establishes a 60:40 joint venture to develop Sunway Medical Centre Putrajaya. The proposed development will be a multi-specialty tertiary hospital with an estimated capacity of 325 beds, located in Precinct 7, Putrajaya, adjacent to Putrajaya Sentral.

(e) On 25 September 2026, SMC entered into a sale and purchase agreement ("SPA") with Sunway Sentral Seremban Sdn Bhd (formerly known as Sunway Bukit Gambier Sdn Bhd), a related party, in relation to the proposed acquisition of a parcel of freehold land measuring approximately 2.1 acres (“Subject Land”), forming part of a parcel of freehold land held under H.S.(D) 278178, P.T. 10433, Bandar Seremban, Daerah Seremban, Negeri Sembilan, for a total purchase consideration of RM10.79 million. The SPA is conditional upon the issuance of the individual title to the Subject Land ("Conditional Precedent"). The Conditional Precedent is to be fulfilled within eighteen (18) months from the date of the SPA ("CP Period"), with an automatic extension of a period of three (3) months thereafter commencing from the date after the expiry of the CP Period or any other extended period as the Parties may mutually agree in writing ("Extended CP Period").

Other than the above, there were no other corporate proposals pending completion as at the date of this interim financial report.

B8. Group Borrowings and Debt Securities

The Group's borrowings as at 30 September 2026 are as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured borrowing			
Medium term notes	96,750	193,500	290,250
Total secured borrowing	**96,750**	**193,500**	**290,250**
Unsecured borrowings			
Receivables financing	122,302	-	122,302
Medium term notes	200,000	700,000	900,000
Banker's acceptances	68,128	-	68,128
Revolving credit	61,320	-	61,320
Total unsecured borrowings	**451,750**	**700,000**	**1,151,750**
Total borrowings	**548,500**	**893,500**	**1,442,000**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B8. Group Borrowings and Debt Securities (Cont'd)

Included in the Group's borrowings as at 30 September 2026 are amounts denominated in currency profile as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured			
Ringgit Malaysia ("RM")	96,750	193,500	290,250
Unsecured			
Ringgit Malaysia ("RM")	268,128	700,000	968,128
United States Dollar ("USD")	183,622	-	183,622
Total borrowings	**548,500**	**893,500**	**1,442,000**

The Group's borrowings as at 31 December 2025 were as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured borrowing			
Medium term notes	-	387,000	387,000
Total secured borrowing	**-**	**387,000**	**387,000**
Unsecured borrowings			
Receivables financing	177,722	-	177,722
Medium term notes	-	900,000	900,000
Banker's acceptances	64,707	-	64,707
Revolving credit	60,875	-	60,875
Total unsecured borrowings	**303,304**	**900,000**	**1,203,304**
Total borrowings	**303,304**	**1,287,000**	**1,590,304**

Included in the Group borrowings as at 31 December 2025 are amounts denominated in currency profile as follows:

	Current RM'000	Non-current RM'000	Total RM'000
Secured			
Ringgit Malaysia ("RM")	-	387,000	387,000
Unsecured			
Ringgit Malaysia ("RM")	124,707	900,000	1,024,707
United States Dollar ("USD")	178,597	-	178,597
Total borrowings	**303,304**	**1,287,000**	**1,590,304**

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B8. Group Borrowings and Debt Securities (Cont'd)

Overall, the total borrowings of the Group have decreased by RM148.3 million, from RM1,590.3 million as at 31 December 2025 to RM1,442.0 million as at 30 September 2026.

	30/09/2026 %	31/12/2025 %
Weighted average interest rate of borrowings	4.17	4.00
Fixed rate instruments	62%	57%
Floating rate instruments	38%	43%
Total	**100%**	**100%**

B9. Financial Instruments - Derivatives

The Group's derivatives as at 30 September 2026 are as follows:

Type of Derivatives	Contract/ Notional Value RM'000	Net Fair Value RM'000	Gain for the period RM'000
Foreign currency forward contracts			
- Less than 1 year	185,443	(1,469)	2,650
Total derivatives	**185,443**	**(1,469)**	**2,650**

Foreign currency forward contracts

The Group has entered into foreign currency forward contracts to hedge the foreign exchange exposure arising from its USD-denominated borrowings. The forward contracts are undertaken on a back-to-back basis with the scheduled repayment dates of the underlying borrowings, thereby mitigating the Group's exposure to fluctuations in the USD/MYR exchange rate. As these contracts are not designated in hedge accounting relationships under MFRS 9 Financial Instruments, all fair value movements are recognised in profit or loss.

As at 30 September 2026, the Group had outstanding foreign currency forward contracts with a total notional value of RM185.4 million. These contracts were in a net fair value liability position of RM1.5 million and generated a fair value gain of RM2.7 million during the financial period. These fair value movements arose from the mark-to-market revaluation of the outstanding forward contracts at the reporting date following changes in USD/MYR exchange rates and forward pricing.

The derivatives are classified as Level 2 fair value measurements within the fair value hierarchy prescribed under MFRS 13 Fair Value Measurement. There were no transfers between Level 1, Level 2 and Level 3 fair value measurements during the financial period.

B10. Fair Value Changes of Financial Liabilities

As at 30 September 2026, other than the derivative financial instruments disclosed in Note B9, the Group did not have any other financial liabilities measured at fair value through profit or loss (“FVTPL”).

[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B11. Aging Analysis of Trade Receivables

The aging analysis of the Group's trade receivables are as follows:

	30/09/2026 RM'000	31/12/2025 RM'000
Current	238,112	212,211
1 to 30 days past due	81,119	36,451
31 to 60 days past due	38,838	19,781
61 to 90 days past due	21,796	10,995
More than 90 days past due	32,395	25,746
Total trade receivables	412,260	305,184

B12. Changes in Material Litigation

There were no material litigation by or against the Group as at 30 September 2026.

B13. Dividends

Other than the dividends paid as disclosed in note A7, no dividend has been proposed by the Board of Directors for the financial period ended 30 September 2026.

B14. Earnings per Share

The profit used as the numerator in calculating basic and diluted earnings per share for the quarter and financial period is as follows:

	Individual Quarter		Cumulative Quarter	
	Current Quarter 30/09/2026 RM'000	Preceding Year Corresponding Quarter 30/09/2025 RM'000	Current Year To Date 30/09/2026 RM'000	Preceding Year Corresponding Period 30/09/2025 RM'000
Basic earnings per share				
Profit attributable to owners of the parent	95,170	59,694	206,657	139,830
Weighted average number of ordinary shares ('000)	11,503,173	11,500,166	11,501,184	11,500,166
Earnings per share (Basic) (sen)	0.83	0.52 [(1)]	1.80	1.22 [(1)]
Diluted earnings per share				
Profit attributable to owners of the parent	95,170	59,694	206,657	139,830
Weighted average number of ordinary shares ('000)	11,517,385	11,500,166	11,510,693	11,500,166
Earnings per share (Diluted) (sen)	0.83	0.52 [(1)]	1.80	1.22 [(1)]

[(1)] For the purpose of EPS (Basic) computation, the weighted average number of ordinary shares in issue for corresponding periods presented is based on the enlarged issued share capital of 11,500,165,558 ordinary shares upon the Listing, in order to provide a consistent and comparable basis across periods.

B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS (CONT'D)

B15. Utilisation of Proceeds from the Public Issue

The utilisation of the RM833.8 million gross proceeds raised by the Group from the Public Issue as at 30 September 2026 is as follows:

Utilisation of proceeds	Proposed utilisation RM'000	Proposed utilisation %	Actual utilisation RM'000	Balance to be utilised RM'000	Timeframe for utilisation
Capital expenditure for expansion of existing hospitals	554,050	66.5%	(66,522)	487,528	Within 36 months
Redemption of Sukuk Wakalah	249,712	29.9%	(49,712)	200,000	Within 24 months
Defray fees and expenses in relation to the IPO and Listing	30,000	3.6%	(30,000) *	-	Within 3 months
	833,762	100.0%	(146,234)	687,528	

* Includes RM16.6 million which has been capitalised as share issuance costs and recognised in the Statements of Changes in Equity.

By Order of the Board

Tan Kim Aun (MAICSA 7002988)
Lee Poh Yean (MAICSA 7015043)

Secretaries

19 November 2026